A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

von Hong, David S., Kurzrock, Razelle, Mulay, Marilyn, Rasmussen, Erik, Wu, Benjamin M., Bass, Michael B., Zhong, Zhandong D., Friberg, Greg, Rosen, Lee S.
Veröffentlicht in Oncotarget (2014)

A Phase 1, Open–label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

von Hong, David S., Gordon, Michael S., Samlowski, Wolfram E., Kurzrock, Razelle, Tannir, Nizar, Friedland, David, Mendelson, David S., Vogelzang, Nicholas J., Rasmussen, Erik, Wu, Benjamin M., Bass, Michael B., Zhong, Zhandong D., Friberg, Gregory, Appleman, Leonard J.
Veröffentlicht in Clin Genitourin Cancer (2013)